New Research And Development License Allows Colorado Firm To Study Cannabis Effect On Alzheimer’s Disease

MedPharm Holdings is planning to be the first one in Denver to study the effects of marijuana on Alzheimer’s disease. Thanks to research and development license recently made available, the company wants to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and the effects of other cannabinoids on Alzheimer’s and dementia patients. While there are medications available for the same, it is only to help deal with the symptoms and not to help with the disease itself. While we know that the plant can help with arthritic pain and epilepsy, we don’t really know if it can help with dementia.

During trials, MedPharm scientists plan to track how cannabinoids interact with neurological receptors through brain mapping and measuring cognitive abilities and patterns in patient demeanor.

Trials are expected to last for about 6-9 months. With plenty of research opportunity at the moment, the Institute of Cannabis Research at the University of Colorado has been working to study the effects of marijuana on cancer and Parkinson’s disease. However, bigger companies are financially more stable to conduct research and get into the industry. For smaller bodies receiving federal funds, there are more at risk.

Read Full Article: https://www.denverpost.com

CBD is one of many powerful cannabinoids found in hemp known for helping to support our body and mind. Here at Healing Dragon CBD we do not intend to make unfounded medical claims about the health benefits of CBD. The FDA has not confirmed that CBD cures, treats, or prevents any diseases or conditions. Before reading this article please take a moment to read our full disclosure statement.